Astellas and Gilead In Spotlight As Compulsory Licensing Pressure Mounts In Chile

Pressure is mounting in Chile for the government to pursue compulsory licensing. Gilead’s Sovadi (sofosbuvir) and Astellas’s prostate cancer drug Xtandi (enzalutamide) could be among the drugs eventually opened up to generic competition.

chess
Pressure is mounting in Chile for the government to act on compulsory licenses

Civil society groups are again calling for the Chilean government to issue compulsory licenses for Astellas Pharma Inc.’s prostate cancer drug Xtandi (enzalutamide) and hepatitis C treatments containing Gilead Sciences Inc.’s sofosbuvir. The move comes after lawmakers passed a resolution calling for the government to introduce measures to facilitate compulsory licensing.

Some 29 patient groups and NGOs from around the world – including Oxfam, Health Action International, Knowledge Ecology International, Colombia’s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet